Rate My Professor Denise Galloway

Galloway's research specializes in the mechanisms by which high-risk HPVs contribute to cancer, including how oncoproteins E6 and E7 disrupt cell cycle checkpoints, DNA damage repair pathways like Fanconi Anemia, and genetic stability, as well as the natural history of genital HPV infections and factors determining progression to cancer. Her work on Merkel cell polyomavirus (MCPyV), associated with 80% of Merkel cell carcinomas, led to a simple blood test for monitoring disease recurrence. Current projects investigate immune responses to HPV infection and vaccination, neutralizing antibodies, optimal vaccine dosing including single-dose efficacy via studies like KEN SHE, and antibody responses to MCPyV tumor antigens. Key publications include 'Analysis of memory B cell responses reveals suboptimal dosing schedule of a licensed vaccine' (Journal of Infectious Diseases, 2018), 'High-risk human papillomavirus oncogenes disrupt the Fanconi Anemia DNA repair pathway by impairing foci formation and de-ubiquitinylation of FancD2' (PLoS Pathogens, 2019), and 'Merkel Cell polyomavirus tumor antigens expressed in Merkel Cell carcinoma function independently of the ubiquitin ligases Fbw7 and b-TrCP' (PLoS Pathogens, 2019). Her contributions have earned the National Cancer Institute Outstanding Investigator Award (2017), election as Fellow of the American Association for Cancer Research Academy (2022), election to the American Academy of Arts and Sciences (2019), and the AACR Team Science Award (2011).